Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
YLL de Mesquita, I Pera Calvi, I Reis Marques… - International Journal of …, 2023 - nature.com
Objectives Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
YLL de Mesquita, P Calvi, R Marques… - … Journal of Obesity …, 2023 - europepmc.org
Objectives Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
YLL de Mesquita, IP Calvi, IR Marques… - … journal of obesity … - pubmed.ncbi.nlm.nih.gov
Objectives Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …